These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
94 related articles for article (PubMed ID: 9588864)
21. Selective killing of HIV-infected cells by anti-gp120 immunotoxins. Matsushita S; Koito A; Maeda Y; Hattori T; Takatsuki K AIDS Res Hum Retroviruses; 1990 Feb; 6(2):193-203. PubMed ID: 2328157 [TBL] [Abstract][Full Text] [Related]
22. In vitro effects of anti-HIV immunotoxins directed against multiple epitopes on HIV type 1 envelope glycoprotein 160. Pincus SH; Wehrly K; Cole R; Fang H; Lewis GK; McClure J; Conley AJ; Wahren B; Posner MR; Notkins AL; Tilley SA; Pinter A; Eiden L; Teintze M; Dorward D; Tolstikov VV AIDS Res Hum Retroviruses; 1996 Jul; 12(11):1041-51. PubMed ID: 8827220 [TBL] [Abstract][Full Text] [Related]
23. Soluble CD4 enhances the efficacy of immunotoxins directed against gp41 of the human immunodeficiency virus. Pincus SH; McClure J Proc Natl Acad Sci U S A; 1993 Jan; 90(1):332-6. PubMed ID: 8419938 [TBL] [Abstract][Full Text] [Related]
24. CD4-Pseudomonas exotoxin hybrid protein blocks the spread of human immunodeficiency virus infection in vitro and is active against cells expressing the envelope glycoproteins from diverse primate immunodeficiency retroviruses. Berger EA; Clouse KA; Chaudhary VK; Chakrabarti S; FitzGerald DJ; Pastan I; Moss B Proc Natl Acad Sci U S A; 1989 Dec; 86(23):9539-43. PubMed ID: 2480605 [TBL] [Abstract][Full Text] [Related]
25. Continuous presence of CD4-PE40 is required for antiviral activity against single-passage HIV isolates and infected peripheral blood mononuclear cells. Winters MA; Merigan TC AIDS Res Hum Retroviruses; 1993 Nov; 9(11):1091-6. PubMed ID: 8312052 [TBL] [Abstract][Full Text] [Related]
26. Design and In Vivo Characterization of Immunoconjugates Targeting HIV gp160. Pincus SH; Song K; Maresh GA; Frank A; Worthylake D; Chung HK; Polacino P; Hamer DH; Coyne CP; Rosenblum MG; Marks JW; Chen G; Weiss D; Ghetie V; Vitetta ES; Robinson JE; Hu SL J Virol; 2017 Feb; 91(3):. PubMed ID: 27795412 [TBL] [Abstract][Full Text] [Related]
27. Elimination of infectious human immunodeficiency virus from human T-cell cultures by synergistic action of CD4-Pseudomonas exotoxin and reverse transcriptase inhibitors. Ashorn P; Moss B; Weinstein JN; Chaudhary VK; FitzGerald DJ; Pastan I; Berger EA Proc Natl Acad Sci U S A; 1990 Nov; 87(22):8889-93. PubMed ID: 1701055 [TBL] [Abstract][Full Text] [Related]
28. A Toxin-Conjugated Recombinant Protein Targeting gp120 and gp41 for Inactivating HIV-1 Virions and Killing Latency-Reversing Agent-Reactivated Latent Cells. Wang X; Xu W; Liu Z; Wu Y; Wang Q; Cao M; Ying T; He N; Lu L; Jiang S mBio; 2022 Feb; 13(1):e0338421. PubMed ID: 35038908 [TBL] [Abstract][Full Text] [Related]
29. AZT demonstrates anti-HIV-1 activity in persistently infected cell lines: implications for combination chemotherapy and immunotherapy. Pincus SH; Wehrly K J Infect Dis; 1990 Dec; 162(6):1233-8. PubMed ID: 2230256 [TBL] [Abstract][Full Text] [Related]
30. Anti-HIV-1 immunotoxin 3B3(Fv)-PE38: enhanced potency against clinical isolates in human PBMCs and macrophages, and negligible hepatotoxicity in macaques. Kennedy PE; Bera TK; Wang QC; Gallo M; Wagner W; Lewis MG; Berger EA; Pastan I J Leukoc Biol; 2006 Nov; 80(5):1175-82. PubMed ID: 16923920 [TBL] [Abstract][Full Text] [Related]
31. Specific killing of HIV-infected lymphocytes by a recombinant immunotoxin directed against the HIV-1 envelope glycoprotein. Bera TK; Kennedy PE; Berger EA; Barbas CF; Pastan I Mol Med; 1998 Jun; 4(6):384-91. PubMed ID: 10780881 [TBL] [Abstract][Full Text] [Related]
32. Human immunodeficiency virus-infected T cells and monocytes are killed by monoclonal human anti-gp41 antibodies coupled to ricin A chain. Till MA; Zolla-Pazner S; Gorny MK; Patton JS; Uhr JW; Vitetta ES Proc Natl Acad Sci U S A; 1989 Mar; 86(6):1987-91. PubMed ID: 2538826 [TBL] [Abstract][Full Text] [Related]
34. Anti-HIV activity of CD4-Pseudomonas exotoxin on infected primary human lymphocytes and monocyte/macrophages. Ashorn P; Englund G; Martin MA; Moss B; Berger EA J Infect Dis; 1991 Apr; 163(4):703-9. PubMed ID: 2010626 [TBL] [Abstract][Full Text] [Related]
35. Unique insertion sequence and pattern of CD4 expression in variants selected with immunotoxins from human immunodeficiency virus type 1-infected T cells. Fang H; Pincus SH J Virol; 1995 Jan; 69(1):75-81. PubMed ID: 7983770 [TBL] [Abstract][Full Text] [Related]
36. [Possible use of anti-envelope immunotoxins against HIV-infection]. Matsushita S; Koito A; Maeda Y; Hattori T; Takatsuki K Nihon Rinsho; 1989 Jan; 47(1):220-6. PubMed ID: 2786096 [No Abstract] [Full Text] [Related]
37. Therapeutic potential of anti-HIV immunotoxins. Pincus SH Antiviral Res; 1996 Dec; 33(1):1-9. PubMed ID: 8955848 [TBL] [Abstract][Full Text] [Related]
38. Inhibition of HIV-1 replication in seropositive patients' CD4+ T-cells by pokeweed antiviral protein-monoclonal antibody conjugates. Zarling JM; Moran PA; Haffar O; Diegel M; Myers DE; Kuelbeck V; Ledbetter JA; Uckun FM Int J Immunopharmacol; 1991; 13 Suppl 1():63-8. PubMed ID: 1688086 [TBL] [Abstract][Full Text] [Related]
39. Characterization of HIV gp120 Envelope Glycoprotein by Lectin Analysis. Gram GJ; Hansen JE Methods Mol Med; 1998; 9():167-74. PubMed ID: 21374458 [TBL] [Abstract][Full Text] [Related]
40. Characterization of in vitro inhibition of human immunodeficiency virus by purified recombinant CD4. Byrn RA; Sekigawa I; Chamow SM; Johnson JS; Gregory TJ; Capon DJ; Groopman JE J Virol; 1989 Oct; 63(10):4370-5. PubMed ID: 2550671 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]